Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Complications of streptococcal tonsillopharyngitis

INTRODUCTION

Pharyngitis due to infection with group A Streptococcus (GAS) is usually a self-limited condition, with symptoms lasting two to five days in untreated patients. When begun within 48 hours of illness, antimicrobial therapy reduced the duration and severity of symptoms by one to two days in double-blind studies and prevented the spread of infection to contacts [1-3]. (See "Treatment and prevention of streptococcal tonsillopharyngitis".)

The other major goal of therapy is to reduce the risk of suppurative and nonsuppurative complications. The potential complications of GAS tonsillopharyngitis will be briefly reviewed here.

NONSUPPURATIVE COMPLICATIONS

The nonsuppurative complications of group A streptococcal (GAS) tonsillopharyngitis include:

Acute rheumatic fever

Scarlet fever

              

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Oct 2014. | This topic last updated: Mar 13, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Randolph MF, Gerber MA, DeMeo KK, Wright L. Effect of antibiotic therapy on the clinical course of streptococcal pharyngitis. J Pediatr 1985; 106:870.
  2. Pichichero ME, Disney FA, Talpey WB, et al. Adverse and beneficial effects of immediate treatment of Group A beta-hemolytic streptococcal pharyngitis with penicillin. Pediatr Infect Dis J 1987; 6:635.
  3. Krober MS, Bass JW, Michels GN. Streptococcal pharyngitis. Placebo-controlled double-blind evaluation of clinical response to penicillin therapy. JAMA 1985; 253:1271.
  4. RAMMELKAMP CH Jr, STOLZER BL. The latent period before the onset of acute rheumatic fever. Yale J Biol Med 1961; 34:386.
  5. Denny FW Jr. A 45-year perspective on the streptococcus and rheumatic fever: the Edward H. Kass Lecture in infectious disease history. Clin Infect Dis 1994; 19:1110.
  6. Stollerman GH. Changing streptococci and prospects for the global eradication of rheumatic fever. Perspect Biol Med 1997; 40:165.
  7. Stollerman GH. Rheumatic fever. Lancet 1997; 349:935.
  8. North DA, Heynes RA, Lennon DR, Neutze J. Analysis of costs of acute rheumatic fever and rheumatic heart disease in Auckland. N Z Med J 1993; 106:400.
  9. Stevens DL. Invasive group A streptococcus infections. Clin Infect Dis 1992; 14:2.
  10. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med 1996; 334:240.
  11. Begovac J, Kuzmanović N, Bejuk D. Comparison of clinical characteristics of group A streptococcal bacteremia in children and adults. Clin Infect Dis 1996; 23:97.
  12. Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989; 321:1.
  13. STETSON CA, RAMMELKAMP CH Jr, KRAUSE RM, et al. Epidemic acute nephritis: studies on etiology, natural history and prevention. Medicine (Baltimore) 1955; 34:431.
  14. Anthony BF, Kaplan EL, Wannamaker LW, et al. Attack rates of acute nephritis after type 49 streptococcal infection of the skin and of the respiratory tract. J Clin Invest 1969; 48:1697.
  15. Rodríguez-Iturbe B. Epidemic poststreptococcal glomerulonephritis. Kidney Int 1984; 25:129.
  16. Tejani A, Ingulli E. Poststreptococcal glomerulonephritis. Current clinical and pathologic concepts. Nephron 1990; 55:1.
  17. Lewy JE, Salinas-Madrigal L, Herdson PB, et al. Clinico-pathologic correlations in acute poststreptococcal glomerulonephritis. A correlation between renal functions, morphologic damage and clinical course of 46 children with acute poststreptococcal glomerulonephritis. Medicine (Baltimore) 1971; 50:453.
  18. Sagel I, Treser G, Ty A, et al. Occurrence and nature of glomerular lesions after group A streptococci infections in children. Ann Intern Med 1973; 79:492.
  19. Bisno, AL, Stevens, DL. Streptococcus pyogenes. In: Principles and Practice of Infectious Diseases, 6th ed, Mandell, GL, Bennett, JE, Dolin, R (Eds), Churchill Livingstone, Philadelphia, PA 2005. p.2362.
  20. Shoemaker M, Lampe RM, Weir MR. Peritonsillitis: abscess or cellulitis? Pediatr Infect Dis 1986; 5:435.
  21. Pichichero, ME. Therapeutic considerations for management of otitis media, sinusitis and tonsillopharyngitis. Pediatr Allergy Immunol 1992; 6:167.
  22. Teele DW, Klein JO, Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis 1989; 160:83.
  23. Stevens DL. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg Infect Dis 1995; 1:69.
  24. Del Mar C. Managing sore throat: a literature review. II. Do antibiotics confer benefit? Med J Aust 1992; 156:644.